J Korean Med Assoc.  2009 Jan;52(1):59-66. 10.5124/jkma.2009.52.1.59.

Recent Trends in Prenatal Diagnosis of Fetal Malformations

Affiliations
  • 1Department of Obstetrics and Gynecology, Kwandong University College of Medicine, Korea. mykimdr@yahoo.co.kr

Abstract

The frequency of fetal malformations accounts for around 3~5% and evaluation of the health of the fetus and screening for fetal malformations has become an important part of prenatal care. Fetal malformations can be classified into structural and chromosomal abnormalities. Improvements in prenatal diagnosis have allowed identification of malformations in fetuses during the first and second trimesters of pregnancy. In prenatal diagnosis, both screening and diagnostic procedures are included. Screening tests include maternal serum aneuploidy screening tests, which are double marker test, triple test, and quadruple test. Recently, first trimester combined ultrasound-biochemical screening and integrated screening were introduced and provided higher detection rates of chromosomal anomalies (ex. Down syndrome). Diagnostic tests are usually performed when screening results are positive and they include chorionic villus sampling, amniocentesis, and percutaneous fetal blood sampling. With highresolution ultrasound equipment, it is now possible to diagnose most structural abnormalities prenatally. On top of that, recent advances in 3D/4D ultrasound have allowed better understanding of fetal anatomy. However, when ultrasound is equivocal, fetal MRI also can be a useful adjuvant in evaluating fetal structural anomalies. Advances in prenatal diagnostic testing have resulted in tremendous benefits to patients and challenges to healthcare providers and new approaches to education and counseling are needed to assure that all patients receive a complete and balanced review of their prenatal diagnostic testing options. This article provides an overview of various screening and diagnostic methods for prenatal diagnosis of fetal malformations.

Keyword

Fetal malformation; Ultrasound; Chromosomal anomaly; Maternal serum aneuploidy screening; 3D/4D ultrasound

MeSH Terms

Amniocentesis
Aneuploidy
Chorionic Villi Sampling
Chromosome Aberrations
Counseling
Diagnostic Tests, Routine
Female
Fetal Blood
Fetus
Health Personnel
Humans
Mass Screening
Pregnancy
Pregnancy Trimester, First
Pregnancy Trimester, Second
Prenatal Care
Prenatal Diagnosis

Figure

  • Figure 1 Measurement of nuchal translucency in the first trimester.

  • Figure 2 Measurement of fetal nasal bone in the first trimester.

  • Figure 3 Example of 3D ultrasound.


Reference

1. Korean society of Obstetrics and Gynecology. Obstetrics. 2007. 4th ed. Seoul: Koonja Publishing;193–197.
2. Reddy Uma M., Filly Roy A., Copel Joshua A.. Prenatal Imaging : Ultrasonography and Magnetic Resonance Imaging. American College of Obstetricans and Gynecologists. Obstet Gynecol. 2008. 112:145–157.
3. Ewigman BG, Crane JP, Frigoletto FD, LeFevre ML, Bain RP, McNellis D. Effect of prenatal ultrasound screening on perinatal outcome. N Engl J Med. 1993. 329:821–827.
Article
4. Diagnostic ultrasound imaging in pregnancy National Institutes of Health Consensus Development Conference Statement February 6-8, 1984. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?indexed=google&rid=hstat6.chapter.49461. Retrieved February 27, 2007.
5. Cicero S, Curcio P, Papageorghiou A, Soneck J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11~14 weeks of gestation: an observational study. Lancet. 2001. 358:1665–1667.
Article
6. Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides K. Maternal serum biochemistry at 11-13+6 weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Prenat Diagn. 2005. 25:977–983.
Article
7. Pitkin RM. Screening and detection of congenital malformation. Am J Obstet Gynecol. 1991. 164:1045–1048.
Article
8. Campbell S, Pearce JM. The prenatal diagnosis of fetal structural anomalies by ultrasound. Clin Obstet Gynaecol. 1983. 10:475–506.
Article
9. Hill LM, Breckle R, Gehrkng WC. Prenatal detection of congenital malformations by ultrasonography. Am J Obstet Gynecol. 1985. 151:44–50.
Article
10. Manchester DK, Pretorius DH, Avery C, Manco-Johnson ML, Wiggins J, Meier PR, Clewell WH. Accuracy of ultrasound diagnoses in pregnancies complicated by suspected fetal anomalies. Prenat Diagn. 1988. 8:109–117.
Article
11. Sabbagha RE, Sheikh Z, Tamura RK. Predictive value, sensitivity, and specificity of ultrasonic targeted imaging for fetal anomalies in gravid women at high risk for birth defects. Am J Obstet Gynecol. 1985. 152:822–827.
Article
12. Filly RA, Cardorza JD, Goldstein RB, Barkovich AJ. Detection of fetal central nervous system anomalies: A practical level of effort for a routine sonogram. Radiology. 1989. 172:309–311.
Article
13. Yeo L, Vintzileos AM. The use of genetic sonography to reduce the need for amniocentesis in women at high-risk for Down syndrome. Semin perinatol. 2003. 27:152–159.
Article
14. Vintzileos AM, Egan JF. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography. Am J Obstet Gynecol. 1995. 17:1639–1640.
Article
15. Benacerraf BR, Nadel AS, Bromley B. Identification of second trimester fetuses with autosomal trisomy by use of a sonographic scoring index. Radiology. 1994. 193:135–140.
Article
16. Nyberg DA, Luthy DA, Resta RG, Nyberg BC, Williams MA. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: Description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol. 1998. 12:8–14.
Article
17. Wax JR, Guilbert J, Mather J, Chen C, Royer D, Steinfeld JD, Ingardia CJ. Efficacy of community-based second trimester genetic ultrasonography in detecting the chromosomally abnormal fetus. J Ultrasound med. 2000. 19:689–694.
Article
18. Gonçalves LF, Lee W, Espinoza J, Romero R. Three- and 4-dimensional ultrasound in obstetric practice: does it help? J Ultrasound Med. 2005. 24:1599–1624.
19. Gonçalve LF, Nien JK, Espinoza J, Kusanovic JP, Lee W, Swope B, Soto E, Treadwell MC, Romero R. What does 2-dimensional imaging add to 3-and 4-dimensional obstetric ultrasonography? J Ultrasound Med. 2006. 25:691–699.
20. Levine D, Barens PD, Madsen JR, Li W, Edelman RR. Fetal central nervous system anomalies: MR imaging augments sonographic diagnosis. Radiology. 1997. 204:635–642.
Article
21. Sponcer K, Spencer CE, Power M, Dawson C, Nicoladies KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum bioche-mistry in a one-step clinic: a review three years prospec-tive experience. BJOG. 2003. 110:281–286.
22. Van Lith JM, Pratt JJ, Beekhuis JR, Mantingh A. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn. 1992. 12:801–806.
Article
23. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn. 1996. 16:143–153.
Article
24. Malone Fergal D, Wald Nicholas J, Canick Jacob A, Ball Robert H, Nybergl David A. First- and second-trimester evaluation of risk (faster): trial principal results of the NICHD multicenter Down syndrome screening study. Am J of Obstet Gynecol. 2003. 189:S. 79.
Article
25. Biggio JR, Morris TC, Owen J, Stringer JSA. An outcome analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. Am J of Obstet Gynecol. 2004. 190:721–729.
Article
Full Text Links
  • JKMA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr